By Dr. Donald L. Gates, MD
Physician-led GLP-1 care starts where a prescription ends. Getting the medication has never been simpler. You fill out a form, a clinician reviews it, and a vial arrives at your door. That part of the process works. The harder part comes three weeks later, when the nausea starts, or the dose changes, or the vial that shows up looks different from the last one.
Those moments are not administrative. They are the treatment.
Obesity Is a Chronic Condition, Not a Transaction
Obesity is a chronic, complex medical condition. It behaves like hypertension or diabetes. It responds to treatment, it requires ongoing management, and it does not resolve because a shipment arrived.
A GLP-1 receptor agonist can meaningfully change appetite and body weight. It does not change the rest of your medical picture. You still have a medication list, a family history, a set of health risks, nutritional needs, and a life that shifts month to month. A treatment plan has to move with those things.
This is where the clinical relationship matters. In a 2025 survey, only 18% of primary care physicians said they felt comfortable with their patients obtaining GLP-1 prescriptions from third-party telehealth prescribers. Sixty-seven percent said the practice may put patient health at risk. Those numbers reflect a concern about continuity, not about technology.
What Physician-Led GLP-1 Care Should Include
Here is what a complete plan looks like. Use it as a checklist for any program you are considering, including ours.
A real clinical assessment. Medical history, current medications, allergies, prior weight-loss treatment, pregnancy plans, contraindications, and your actual goals. GLP-1 therapy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. That is not a checkbox question. It requires a conversation.
A discussion of options. FDA-approved medications should be considered first when they are appropriate and available. If a compounded product enters the conversation, its non-FDA-approved status has to be stated plainly. Compounded drugs are not reviewed by the FDA’s concerns with unapproved GLP-1 drugs before they reach patients.
Dosing education you can repeat back. You should be able to name the drug, the ingredient form, the concentration, your prescribed dose in milligrams, the matching volume in milliliters, and the marking on your syringe. This matters most with multi-dose vials, where concentrations vary between products.
A scheduled follow-up. Not an open invitation to message someone if things go wrong. An actual appointment on an actual calendar. Learn more about GLP-1 follow-up care.
A defined way to reach the clinical team. You should know the routine contact method, the usual response window during business hours, how urgent concerns get triaged, and where to go after hours.
A plan that extends past the scale. Nutrition, hydration, activity, muscle preservation, sleep, cardiometabolic health, and what maintenance looks like a year from now. See our guide to lab monitoring during GLP-1 therapy.
Convenience and Continuity Are Different Things
Fast is not the same as good, and slow is not the same as careful. Plenty of telehealth programs employ licensed clinicians and offer genuine provider messaging. Plenty of in-person clinics do a thin job. The setting is not the variable that matters.
What matters is whether the standard of care is visible. You should not have to guess who prescribed your medication, which pharmacy dispensed it, whether that pharmacy holds an active license, or when someone will check on you next.
Physician-led GLP-1 care makes those answers easy to find. That is the whole point.
The Question Worth Asking
Before you enroll anywhere, ask yourself one thing:
If I develop a concerning symptom tomorrow, can I reach a clinician who knows my history, can evaluate the situation, and can tell me what to do next?
If the answer is yes, the program is probably built correctly. If the answer is unclear, that uncertainty will cost you at exactly the moment it matters most.
Frequently Asked Questions
Do I need to see a doctor in person to get a GLP-1?
Not always. Requirements vary by state and by clinical situation. An in-person visit does allow a physical examination, baseline lab work, and medication reconciliation that a questionnaire cannot replicate. For patients with diabetes, fatty liver disease, hypertension, or complex medication lists, that additional information is clinically useful.
Is a compounded GLP-1 the same as Ozempic or Wegovy?
No. Compounded medications are not FDA-approved and are not generic versions of approved drugs. The FDA has stated that compounded GLP-1 drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved product. National shortages of semaglutide and tirzepatide injections have been declared resolved, which narrows that window considerably.
How long will I be on a GLP-1 medication?
That depends on your response, your tolerability, your other conditions, and your goals. Obesity is a chronic condition, and the published evidence on discontinuation shows that weight regain is common. Long-term planning should be part of the conversation before you start, not after.
This article is educational and is not a substitute for individualized medical advice. Treatment decisions depend on your medical history, current medications, and clinical circumstances. Talk with a physician before starting, changing, or stopping any medication. If symptoms are severe, rapidly worsening, or feel like an emergency, call 911 or seek emergency care.
About the Author: Dr. Donald L. Gates, MD leads Scale Solutions, a medical weight management practice serving Savannah, Pooler, and coastal Georgia. He earned his medical degree at Loma Linda University and practiced emergency medicine before focusing his career on bariatric and metabolic medicine. At Scale Solutions he treats obesity as the chronic medical condition it is, combining GLP-1 therapy with nutrition counseling and long-term follow-up care.